Strategies for achieving viral hepatitis C micro-elimination in the Netherlands - PubMed
- ️Mon Jan 01 2018
Review
Strategies for achieving viral hepatitis C micro-elimination in the Netherlands
P A M Kracht et al. Hepatol Med Policy. 2018.
Abstract
The Netherlands is striving to achieve national elimination of the hepatitis C virus (HCV) as one of the first countries worldwide. The favorable HCV epidemiology with both low prevalence and incidence, together with access to care and treatment, present excellent conditions to further build on towards this objective. The Dutch national plan on viral hepatitis, introduced in 2016, defines targets in the HCV healthcare cascade and provides a structural framework for the development of elimination activities. Since many different stakeholders are involved in HCV care in the Netherlands, focus has been placed on micro-elimination initiatives as a pragmatic and efficient approach. These numerous micro-eliminations projects have brought the Netherlands closer to HCV elimination. In the near future, efforts specifically have to be made in order to optimize case-finding strategies and to successfully accomplish the nationwide implementation of the registration and monitoring system of viral hepatitis mono-infections, before this final goal can be reached. The upcoming years will then elucidate if the Dutch' hands on approach has resulted in sufficient progress against HCV and if the Netherlands will lead the way towards nationwide HCV elimination.
Keywords: Hep-CORE, HCV cascade of care; Hepatitis C virus; Micro-elimination.
Conflict of interest statement
Not applicable.Not applicable.AH: advisory boards: Abbvie, BMS, Gilead, Janssen, MSD; consultancy: AbbVie; financial support for HCV retrieval project from Abbvie, BMS, Gilead and MSD; JA: advisory boards: Abbvie, BMS, Gilead, Janssen, MSD and ViiV; research grants: AbbVie, BMS; KvE: advisory boards: Abbvie, BMS, Gilead, Janssen-Cilag; Support for HCV patient care path from Abbvie, Gilead, Janssen-Cilag. The other authors declare that they have no competing interest.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures
Similar articles
-
Isfordink CJ, van Dijk M, Brakenhoff SM, Kracht PAM, Arends JE, de Knegt RJ, van der Valk M, Drenth JPH; CELINE Study Group. Isfordink CJ, et al. Eur J Intern Med. 2022 Jul;101:93-97. doi: 10.1016/j.ejim.2022.04.024. Epub 2022 May 5. Eur J Intern Med. 2022. PMID: 35527178
-
Kracht PAM, de Gee EA, van der Poel A, Verhagen MAMT, Hoepelman AIM, Croes EA, Arends JE. Kracht PAM, et al. Harm Reduct J. 2019 Jul 15;16(1):45. doi: 10.1186/s12954-019-0316-4. Harm Reduct J. 2019. PMID: 31307470 Free PMC article.
-
van Dijk M, Brakenhoff SM, Isfordink CJ, Cheng WH, Blokzijl H, Boland G, Dofferhoff ASM, van Hoek B, van Nieuwkoop C, Sonneveld MJ, van der Valk M, Drenth JPH, de Knegt RJ. van Dijk M, et al. J Clin Med. 2021 Sep 30;10(19):4562. doi: 10.3390/jcm10194562. J Clin Med. 2021. PMID: 34640576 Free PMC article.
-
Papatheodoridis GV, Hatzakis A, Cholongitas E, Baptista-Leite R, Baskozos I, Chhatwal J, Colombo M, Cortez-Pinto H, Craxi A, Goldberg D, Gore C, Kautz A, Lazarus JV, Mendão L, Peck-Radosavljevic M, Razavi H, Schatz E, Tözün N, van Damme P, Wedemeyer H, Yazdanpanah Y, Zuure F, Manns MP. Papatheodoridis GV, et al. J Viral Hepat. 2018 Mar;25 Suppl 1:6-17. doi: 10.1111/jvh.12875. J Viral Hepat. 2018. PMID: 29508946 Review.
-
van Dijk M, Drenth JPH; HepNed study group. van Dijk M, et al. J Viral Hepat. 2020 Dec;27(12):1270-1283. doi: 10.1111/jvh.13399. Epub 2020 Sep 22. J Viral Hepat. 2020. PMID: 32964615 Free PMC article. Review.
Cited by
-
Eijsink JFH, Al Khayat MNMT, Boersma C, Ter Horst PGJ, Wilschut JC, Postma MJ. Eijsink JFH, et al. Eur J Health Econ. 2021 Feb;22(1):75-88. doi: 10.1007/s10198-020-01236-2. Epub 2020 Oct 16. Eur J Health Econ. 2021. PMID: 33064259 Free PMC article.
-
Von den Hoff DW, Berden FAC, Atsma F, Schellekens AFA, Drenth JPH. Von den Hoff DW, et al. J Clin Med. 2022 Feb 21;11(4):1146. doi: 10.3390/jcm11041146. J Clin Med. 2022. PMID: 35207419 Free PMC article.
-
Dröse S, Øvrehus ALH, Holm DK, Madsen LW, Mössner BK, Søholm J, Hansen JF, Røge BT, Christensen PB. Dröse S, et al. BMC Infect Dis. 2022 Mar 1;22(1):202. doi: 10.1186/s12879-022-07196-7. BMC Infect Dis. 2022. PMID: 35232372 Free PMC article.
-
Impact of voluntary testing on infectious disease epidemiology: A game theoretic approach.
Pepiot A, Supervie V, Breban R. Pepiot A, et al. PLoS One. 2023 Nov 7;18(11):e0293968. doi: 10.1371/journal.pone.0293968. eCollection 2023. PLoS One. 2023. PMID: 37934734 Free PMC article.
-
Hepatitis C micro-elimination through the retrieval strategy of patients lost to follow-up.
Chen CJ, Huang YH, Hsu CW, Chen YC, Chang ML, Lin CY, Shen YH, Chien RN. Chen CJ, et al. BMC Gastroenterol. 2023 Feb 13;23(1):40. doi: 10.1186/s12876-023-02665-y. BMC Gastroenterol. 2023. PMID: 36782112 Free PMC article.
References
-
- World Health Organization . Global health sector strategy on viral hepatitis 2016–2021. 2016.
-
- Hogenbirk R, David S, van Steenbergen J, Urbanus A. Meer dan opsporen, Nationaal hepatitisplan: een strategie voor actie. 2016. http://www.rivm.nl/dsresource?objectid=119820d5-d1fe-440f-83cf-ffb7478f0.... Accessed 2 Apr 2018.
-
- Health Council of the Netherlands. Screening risk groups for hepatitis B and C. The Hague: Health Council of the Netherlands; 2016. https://www.gezondheidsraad.nl/documenten/adviezen/2016/11/01/screening-.... Accessed 2 Apr 2018
-
- Veldhuijzen IK, Conyn-van Spaendonck MAE, Dorigo-Zetsma JW. Seroprevalence of hepatitis B and C in the Dutch population. Infect Bull. 1999;10:182–184.
Publication types
LinkOut - more resources
Full Text Sources